8-K: C4 Therapeutics Reports Strong Cemsidomide Phase 1 Data

C4 Therapeutics, Inc. announced positive Phase 1 clinical trial data for cemsidomide in relapsed/refractory multiple myeloma and outlined an accelerated path to registration, while also terminating a sales agreement prospectus.

Summary

• Positive Phase 1 data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM) was reported.
• Cemsidomide achieved an Overall Response Rate (ORR) of 53% and a Clinical Benefit Rate (CBR) of 63% at the 100g dose level in RRMM patients.
• One patient at the 100g dose level achieved MRD negativity with a Complete Response (CR).
• The drug demonstrated a differentiated safety and tolerability profile, with minimal dose reductions (6% of 73 patients) and no discontinuations related to cemsidomide.
• The company plans to initiate a Phase 2 trial of cemsidomide + dexamethasone in 4L+ RRMM in Q1 2026, with initial ORR data expected in 2H 2027.
• A Phase 1b trial of cemsidomide + elranatamab in 2L+ RRMM is expected to start in Q2 2026, with data anticipated by mid-2027, both aiming for potential accelerated approvals.
• The sales agreement prospectus with TD Securities (USA) LLC, dated November 13, 2024, was terminated effective October 16, 2025, halting further common stock sales under that specific prospectus.
• As of June 30, 2025, 3,769,483 shares were sold under the terminated prospectus for gross proceeds of approximately $9.6 million.
• The CFT1946 program (BRAF V600 Mutant Cancers) will not advance beyond Phase 1, and the company is seeking a partnership for it.
• The collaboration with Merck will conclude in late November 2025.
• A new discovery strategy focuses on novel targets in non-oncology (immunology, neuroinflammation/neurodegeneration) and oncology, with a goal of 3 Investigational New Drug (IND) applications by the end of 2028.

Sentiment

Score: 8

Explanation: The positive Phase 1 clinical data for cemsidomide, especially the high ORR in a heavily pre-treated population and the clear path to accelerated approval, is a significant positive. While the termination of the prospectus and the discontinuation of CFT1946 are minor negatives, the overall outlook for the lead asset and the strategic pipeline adjustments are strong.

Positives

• Strong Phase 1 clinical data for cemsidomide in RRMM, showing a 53% ORR and 63% CBR at the highest dose level (100g) in a heavily pre-treated population.
• Cemsidomide demonstrated a differentiated safety and tolerability profile with low rates of dose reductions (6%) and no drug-related discontinuations.
• Evidence of T-cell activation and sustained IKZF1/3 degradation supports the drug's mechanism of action and potential for enhanced immunomodulatory effects.
• A clear and accelerated development path for cemsidomide has been outlined, with two distinct potential accelerated approval opportunities in multiple myeloma.
• A high percentage (84%) of patients at the 100g dose level had received prior CAR-T or T-cell engager therapy, indicating efficacy in a challenging, heavily pre-treated patient population.
• 67% (10/15) of efficacy evaluable patients who achieved a Partial Response (PR) or better at the two highest dose levels (75g and 100g) remain on treatment, suggesting durable responses.

Negatives

• The termination of the sales agreement prospectus means no further capital can be raised through that specific facility without filing a new prospectus.
• The CFT1946 program will not advance beyond Phase 1, indicating a pipeline setback for that specific asset and a need to seek partnership.
• The collaboration with Merck will conclude in late November 2025, potentially impacting future collaborative research or funding.
• Median Progression-Free Survival (PFS) was 3.7 months across all doses, which, while in a heavily pre-treated population, highlights the aggressive nature of the disease.
• High rates of neutropenia (61% all grades, 57% Grade 3/4) and infections (58% all grades) were observed with cemsidomide + dexamethasone, requiring careful management.

Risks

• Uncertainties are associated with research and development, clinical trials, and related regulatory reviews and approvals.
• Product candidates may not demonstrate success in future clinical trials, potentially leading to development failures.
• Actual results could vary significantly from forward-looking statements, impacting investor expectations.
• The company's financial condition and results of operations could be materially adversely affected by unforeseen events or market conditions.
• Reliance on estimates, forecasts, and market research for market sizing and prevalence data is inherently subject to uncertainties.
• The risk of neutropenia and infections with cemsidomide treatment requires ongoing monitoring and management, which could impact patient compliance or broader adoption.
• The company's ability to successfully manufacture and supply its product candidates for clinical trials is crucial for continued development.
• The ability to fund future operations is dependent on successful capital raises or partnerships, especially after terminating the current sales prospectus.

Future Outlook

C4 Therapeutics anticipates advancing cemsidomide through Phase 2 and Phase 1b trials in 2026, targeting accelerated approvals in relapsed/refractory multiple myeloma, with initial data expected in mid-2027 and 2H 2027. The company also plans to make a Go/No Go decision for CFT8919 in Q1 2026 and aims for three Investigational New Drug (IND) applications from its discovery pipeline by the end of 2028, focusing on non-oncology and oncology indications. The Merck collaboration will conclude in late November 2025.

Management Comments

• C4T is positioned to unlock value across the portfolio.
• Deliver value from high-potential clinical programs.
• Advance cemsidomide to realize its potential as an IKZF1/3 degrader with class-leading efficacy and a differentiated safety & tolerability profile.
• Utilize CFT8919 Phase 1 data to determine next steps.
• Expand application of targeted protein degradation through high-value collaborations.
• Cemsidomide development plan provides efficient path to registration and addresses a growing patient population.

Industry Context

The multiple myeloma market is growing, with a significant unmet need, especially in later lines of therapy where patients continue to progress despite novel treatments like BCMA CAR-Ts and BiTEs. Cemsidomide, by activating T-cells and demonstrating a differentiated profile, aims to enhance the efficacy of BCMA BiTEs, potentially capturing market share from CAR-Ts by offering a more convenient regimen with comparable efficacy. The targeted protein degradation (TPD) field is evolving, with C4T adjusting its discovery strategy to focus on first-in-class opportunities in validated pathways, including neuroinflammation and immunology, where degraders may offer unique advantages over traditional inhibitors.

Comparison to Industry Standards

• Cemsidomide's 53% Overall Response Rate (ORR) at the 100g dose level in heavily pre-treated relapsed/refractory multiple myeloma (RRMM) patients (84% prior CAR-T/T-cell engager) is competitive, especially when considering the ORR range of BCMA BiTEs (58%-70%) and CAR-Ts (~85%) in broader populations, suggesting potential to bridge the efficacy gap.
• The differentiated safety and tolerability profile of cemsidomide, characterized by minimal dose reductions (6%) and no drug-related discontinuations, positions it favorably against other IKZF1/3 degraders or similar agents that may have more challenging safety profiles.
• The estimated peak revenue potential of $2.5B-$4B for cemsidomide indicates a significant market opportunity, aligning with the projected growth trajectory of the BCMA CAR-T and BiTE market, which is predicted to grow at approximately 50% Compound Annual Growth Rate (CAGR).
• The company's strategic shift in discovery to target areas like neuroinflammation and immunology, where biologics often fail to meet patient needs, aligns with a broader industry trend of exploring novel modalities for challenging indications.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data and an accelerated development path for cemsidomide. There is a risk of dilution if new capital is raised in the future.
• Patients: The positive data offers hope for a new, effective, and well-tolerated treatment option for relapsed/refractory multiple myeloma, a disease with significant unmet needs.
• Investment Professionals/Analysts: The new data provides clearer insights into the company's lead asset and future prospects, enabling more informed analysis and valuation.
• Regulatory Authorities: Will review the presented data and proposed development plans for cemsidomide as the company pursues accelerated approval pathways.
• Employees: Strategic pipeline adjustments and continued clinical progress provide clarity and focus for research and development efforts.

Next Steps

• Formally align with the FDA on the Recommended Phase 2 Dose (RP2D) for cemsidomide by year-end 2025.
• Initiate a Phase 2 trial of cemsidomide + dexamethasone in 4L+ RRMM in Q1 2026.
• Initiate a Phase 1b trial of cemsidomide + elranatamab in 2L+ RRMM in Q2 2026.
• Utilize Phase 1 data from CFT8919 in Greater China to inform ex-China clinical development and make a Go/No Go decision in Q1 2026.
• Seek partnership for the CFT1946 BRAF program.
• Advance a new portfolio of novel targets in non-oncology and oncology indications, with potential for multiple development candidates and 3 Investigational New Drug (IND) applications by the end of 2028.
• Present and publish preclinical work from the internal pipeline and TORPEDO platform.

Key Dates

Recommendation

The strong Phase 1 data for cemsidomide, demonstrating a 53% Overall Response Rate (ORR) in a heavily pre-treated multiple myeloma population with a differentiated safety profile, significantly de-risks the lead asset. The outlined accelerated development pathway with two potential accelerated approvals provides a clear and relatively fast path to market. While the termination of the specific sales prospectus and the discontinuation of CFT1946 are minor setbacks, the overall positive clinical results for cemsidomide, its large market potential, and the strategic focus on high-value targets outweigh these. The company appears well-positioned for future growth, making it an attractive investment.

Keywords

C4 Therapeutics, Cemsidomide, Multiple Myeloma, IKZF1/3 degrader, Targeted Protein Degradation, Oncology, Clinical Trial, Phase 1, Dexamethasone, Elranatamab, SEC Filing, Biotechnology, Pharmaceutical, Drug Development, Cancer Treatment, Relapsed/Refractory, TD Cowen, Capital Raise, Pipeline, Neutropenia, T-cell activation